 |
|
Altered CD4+/CD8+ T-Cell Ratios in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis
Olaf Stüve, MD, PhD;
Christina M. Marra, MD;
Amit Bar-Or, MD;
Masaaki Niino, MD;
Petra D. Cravens, PhD;
Sabine Cepok, PhD;
Elliot M. Frohman, MD, PhD;
J. Theodore Phillips, MD, PhD;
Gabriele Arendt, MD;
Keith R. Jerome, MD, PhD;
Linda Cook, PhD;
Francois Grand'Maison, MD;
Bernhard Hemmer, MD;
Nancy L. Monson, PhD;
Michael K. Racke, MD
Arch Neurol. 2006;63:1383-1387.
Background Treatment with natalizumab, a monoclonal antibody against the adhesion molecule very late activation antigen 4, an  4 1 integrin, was recently associated with the development of progressive multifocal leukoencephalopathy, a demyelinating disorder of the central nervous system caused by JC virus infection.
Objective To test the effect of natalizumab treatment on the CD4+/CD8+ T-cell ratios in cerebrospinal fluid (CSF) and peripheral blood.
Design Prospective longitudinal study.
Setting Academic and private multiple sclerosis centers.
Patients Patients with multiple sclerosis (MS) treated with natalizumab, untreated patients with MS, patients with other neurologic diseases, and human immunodeficiency virus–infected patients.
Main Outcome Measures CD4+ and CD8+ T cells were enumerated in CSF and peripheral blood. The mean fluorescence intensity of unbound 4 integrin on peripheral blood CD4+ and CD8+ T cells was analyzed before and after natalizumab therapy.
Results Natalizumab therapy decreased the CSF CD4+/CD8+ ratio of patients with MS to levels similar to those of human immunodeficiency virus–infected patients. CD4+/CD8+ ratios in peripheral blood in patients with MS progressively decreased with the number of natalizumab doses, but they remained within normal limits. Six months after the cessation of natalizumab therapy, CSF CD4+/CD8+ ratios normalized. The expression of unbound 4 integrin on peripheral blood T cells decreases with natalizumab therapy and was significantly lower on CD4+ vs CD8+ T cells.
Conclusions Natalizumab treatment alters the CSF CD4+/CD8+ ratio. Lower expression of unbound 4 integrin on CD4+ T cells is one possible mechanism. These results may have implications for the observation that some natalizumab-treated patients with MS developed progressive multifocal leukoencephalopathy.
Author Affiliations: Department of Neurology (Drs Stüve, Cravens, Frohman, Monson, and Racke) and Center for Immunology (Drs Monson and Racke), University of Texas Southwestern Medical Center at Dallas; Neurology Section, VA North Texas Health Care System, Medical Service, Dallas (Dr Stüve); Departments of Neurology (Dr Marra) and Laboratory Medicine (Drs Jerome and Cook), University of Washington, Seattle; Department of Neurology and Neurosurgery, Montreal Neurological Institute (Drs Bar-Or and Niino), and Department of Microbiology and Immunology (Dr Bar-Or), McGill University, Montreal, Quebec; Fred Hutchinson Cancer Research Center, Seattle (Drs Jerome and Cook); Department of Neurology, Heinrich Heine University, Düsseldorf, Germany (Drs Stüve, Cepok, Arendt, and Hemmer); Multiple Sclerosis Center at Texas Neurology, Dallas (Dr Phillips); and MS Clinic l'Hôpital Charles LeMoyne, Montreal (Dr Grand'Maison).
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
Natalizumab and Immune Cells
Henry F. McFarland and Steven Jacobson
Arch Neurol. 2006;63(10):1366-1367.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Intrathecal effects of daclizumab treatment of multiple sclerosis
Bielekova et al.
Neurology 2011;77:1877-1886.
ABSTRACT
| FULL TEXT
Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS
Kowarik et al.
Neurology 2011;76:1214-1221.
ABSTRACT
| FULL TEXT
Translational Research in Neurology and Neuroscience 2010: Multiple Sclerosis
Stuve et al.
Arch Neurol 2010;67:1307-1315.
ABSTRACT
| FULL TEXT
IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME AFTER WITHDRAWAL OF NATALIZUMAB?
Lenhard et al.
Neurology 2010;75:831-833.
FULL TEXT
Natalizumab and Progressive Multifocal Leukoencephalopathy: What Are the Causal Factors and Can It Be Avoided?
Warnke et al.
Arch Neurol 2010;67:923-930.
ABSTRACT
| FULL TEXT
Progressive Multifocal Leukoencephalopathy: What's New?
Focosi et al.
Neuroscientist 2010;16:308-323.
ABSTRACT
Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid
Mellergard et al.
Mult Scler 2010;16:208-217.
ABSTRACT
OCULAR TOXOPLASMOSIS DURING NATALIZUMAB TREATMENT
Zecca et al.
Neurology 2009;73:1418-1419.
FULL TEXT
The Binding Specificity and Selective Antagonism of Vedolizumab, an Anti-{alpha}4{beta}7 Integrin Therapeutic Antibody in Development for Inflammatory Bowel Diseases
Soler et al.
J. Pharmacol. Exp. Ther. 2009;330:864-875.
ABSTRACT
| FULL TEXT
Emerging Viral Infections of the Central Nervous System: Part 2
Tyler
Arch Neurol 2009;66:1065-1074.
ABSTRACT
| FULL TEXT
Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells
Kivisakk et al.
Neurology 2009;72:1922-1930.
ABSTRACT
| FULL TEXT
Natalizumab in the treatment of multiple sclerosis.
Yaldizli and Putzki
Therapeutic Advances in Neurological Disorders 2009;2:115-128.
ABSTRACT
Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy
Stuve et al.
Neurology 2009;72:396-401.
ABSTRACT
| FULL TEXT
Central Nervous System Immune Surveillance: On Natalizumab, Dendritic Cells, and Dangerous Immune Privilege
Becher
Arch Neurol 2008;65:1566-1567.
FULL TEXT
Decrease in the Numbers of Dendritic Cells and CD4+ T Cells in Cerebral Perivascular Spaces Due to Natalizumab
Martin et al.
Arch Neurol 2008;65:1596-1603.
ABSTRACT
| FULL TEXT
Natalizumab: benefit outweighs risk in selected patients with multiple sclerosis.
Phillips and Frohman
Therapeutic Advances in Neurological Disorders 2008;1:151-153.
Natalizumab: Increased Vigilance is Required in Treating Patients with Multiple Sclerosis.
Racke and Stuve
Therapeutic Advances in Neurological Disorders 2008;1:155-156.
Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis
Krumbholz et al.
Neurology 2008;71:1350-1354.
ABSTRACT
| FULL TEXT
JC viral loads in patients with Crohn's disease treated with immunosuppression: can we screen for elevated risk of progressive multifocal leukoencephalopathy?
Verbeeck et al.
Gut 2008;57:1393-1397.
ABSTRACT
| FULL TEXT
Recent and future advances in the treatment of status epilepticus.
Linker and Kieseier
Therapeutic Advances in Neurological Disorders 2008;1:33-42.
ABSTRACT
Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab
Bonig et al.
Blood 2008;111:3439-3441.
ABSTRACT
| FULL TEXT
E- and P-Selectin Are Not Required for the Development of Experimental Autoimmune Encephalomyelitis in C57BL/6 and SJL Mice
Doring et al.
J. Immunol. 2007;179:8470-8479.
ABSTRACT
| FULL TEXT
High Incidence of Post-Lumbar Puncture Headaches in Patients With Multiple Sclerosis Treated With Natalizumab: Role of Intrathecal Leukocytes
Stuve et al.
Arch Neurol 2007;64:1055-1056.
FULL TEXT
Potential Risk of Progressive Multifocal Leukoencephalopathy With Natalizumab Therapy: Possible Interventions
Stuve et al.
Arch Neurol 2007;64:169-176.
ABSTRACT
| FULL TEXT
Natalizumab and immune cells.
McFarland and Jacobson
Arch Neurol 2006;63:1366-1367.
FULL TEXT
|
